Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Phase 2

1(12.5%)

8Total

Phase 1(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07550374Phase 1Not Yet Recruiting

Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery

Role: lead

NCT07289477Phase 1Recruiting

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

Role: lead

NCT07102342Phase 1Recruiting

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Role: lead

NCT06612710Phase 1Recruiting

The Safety and Efficacy of NouvSoma001 in Ischemic Stroke

Role: collaborator

NCT06620809Phase 1Recruiting

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

Role: collaborator

NCT07028632Phase 2Not Yet Recruiting

The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

Role: lead

NCT06608355Phase 1Recruiting

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease